25 May 2024 in Endocrine Reviews
Glucocorticoid (GC) hormones are secreted in a circadian and ultradian rhythm and play a critical role in maintaining physiological homeostasis, with both excess and insufficient GC associated with adverse effects on health. Current assessment of GC status is primarily clinical, often in conjunction with serum cortisol values, which may be stimulated or suppressed depending on the GC disturbance being assessed. In the setting of extreme perturbations in cortisol levels ie, markedly low or high levels, symptoms and signs of GC dysfunction may be overt. However, when disturbances in cortisol GC status values are less extreme, such as when assessing optimization of a GC replacement regimen, signs and symptoms can be more subtle or nonspecific. Current tools for assessing GC status are best suited to identifying profound disturbances but may lack sensitivity for confirming optimal GC status. Moreover, single cortisol values do not necessarily reflect an individual's GC status, as they are subject to inter- and intraindividual variation and do not take into account the pulsatile nature of cortisol secretion, variation in binding proteins, or local tissue concentrations as dictated by 11beta-hydroxysteroid dehydrogenase activity, as well as GC receptor sensitivity. In the present review, we evaluate possible alternative methods for the assessment of GC status that do not solely rely on the measurement of circulating cortisol levels. We discuss the potential of changes in metabolomic profiles, micro RNA, gene expression, and epigenetic and other novel biomarkers such as growth differentiating factor 15 and osteocalcin, which could in the future aid in the objective classification of GC status.
27 May 2024 in Clinical Endocrinology
Background: Adrenal insufficiency (AI) is a life‐threatening condition which requires long term glucocorticoid replacement. The insulin tolerance test (ITT) is the current gold standard test for diagnosis of secondary AI, but the widely accepted cut‐off value of a peak cortisol of less than 500 nmol/L assumes that anyone who does not reach this value has AI and thus requires full replacement. The cut‐off used to diagnose AI is also founded on outdated assays. Use of this cut‐off in an era of more specific immunoassays therefore risks misdiagnosis, subsequent unnecessary glucocorticoid exposure and associated adverse effects with increased mortality risk.Design, Patients and Measurements: This retrospective analysis assessed 300 ITT cortisol responses using the Abbott Architect and Alinity analyser platforms in patients with suspected AI over a period of 12 years (August 2010 to January 2022), at a tertiary centre.Results: Patients were classified as having AI or not, based on a comprehensive clinical review of electronic patient records from the point of test to the present day by a panel of pituitary and adrenal specialists. Using the current institutional cut‐off value of 500 nmol/L, receiver operating characteristic analysis identified a 100.0% sensitivity and 43.6% specificity (area under the curve 0.979). Using a lower cortisol threshold value of 416 nmol/L on the Abbott analyser platform maintained a sensitivity of 100.0% and improved the specificity to 86.7%.Conclusion: This data supports lowering the Abbott analyser ITT peak cortisol threshold to 416 nmol/L. Use of this improved cut‐off avoids unnecessary glucocorticoid replacement therapy in 104 (34.7%) of individuals in this study. All patients remained well with at least 1 year longitudinal follow up of glucocorticoid replacement.
5 December 2024 in Clinical Endocrinology
Objective: An incorrect diagnosis of arginine vasopressin deficiency and resistance (AVP‐D and AVP‐R) results in the potentially dangerous use of desmopressin in healthy individuals. The water deprivation test is a central diagnostic test in patients with polydipsia polyuria syndrome (PPS). This study aims to determine the effectiveness of the current interpretation of reference ranges.Methods: This is a retrospective analysis of 135 patients who underwent a water deprivation test between August 2014 and August 2023. All patient diagnoses were reviewed, and variability and receiver operating characteristic (ROC) curves were determined for serum osmolality, serum sodium and urine osmolality.Results: Serum sodium demonstrated reduced variability compared with serum osmolality (0.72% vs. 1.16%, respectively, 37.5% reduction; p < 0.001). The standard serum osmolality cut‐off value of ≥ 300 mOsm/kg in diagnosing AVP‐D, AVP‐R, and primary polydipsia (PP) achieved a sensitivity of 76.19% and specificity of 76.92%. A serum sodium cut‐off value of ≥ 148 mmol/L demonstrated 100% specificity in excluding PP. This cut‐off was used alongside urine osmolality cut‐off values of > 630 mOsm/kg (for PP) and < 383 mOsm/kg (for AVP‐D/AVP‐R). Review of post‐desmopressin urine osmolality and clinical monitoring was performed in equivocal diagnostic cases (n = 6), achieving 100% sensitivity and 100% specificity within the study sample.Conclusions: This study demonstrates that a serum sodium cut‐off of ≥ 148 mmol/L in tandem with urine osmolality yields the best diagnostic accuracy to differentiate between AVP‐D, AVP‐R, and PP. Serum sodium may be more reliable than serum osmolality in the investigation of patients with PPS, demonstrating lower biological and analytical variability.
1 February 2026 in Endocrine Connections
Background: Patients with adrenal insufficiency require glucocorticoid replacement therapy either as hydrocortisone in multiple-daily doses or as low-dose prednisolone once daily. Data on the long-term safety, cardiovascular risk, and quality-of-life (QoL) outcomes of prednisolone remain limited. Methods: In this prospective longitudinal cohort study, patients with adrenal insufficiency underwent a pre-specified switch from multiple-daily dose hydrocortisone to once-daily low-dose prednisolone (2–4 mg) as part of routine clinical care and followed up for at least four months. Cardiovascular risk was assessed using anthropometric and biochemical markers (lipid profile, HbA1c, C-reactive protein, blood pressure, and waist and hip circumference). QoL was evaluated using a modified SF-36 questionnaire. Baseline and follow-up measures were compared using paired t-tests or non-parametric equivalents. Results: Of the 62 enrolled patients, 48 completed follow-up. The mean age was 54.5 ± 13 years; 56% were female; and 83% had secondary adrenal insufficiency. After at least four months on prednisolone, weight decreased significantly (90.6–89.6 kg, P = 0.007), accompanied by a reduction in systolic blood pressure (−5 mmHg, P = 0.032). Lipid parameters, HbA1c, and CRP remained unchanged (P > 0.05). Energy scores improved significantly (+9 points, P = 0.003), and patients reported increased treatment convenience (P = 0.002). Conclusion: Low-dose once-daily prednisolone offers comparable cardiovascular risk to hydrocortisone while improving treatment convenience, systolic blood pressure, and SF-36 subjective energy scores. These findings support the use of prednisolone as a potentially preferable alternative in patients with adrenal insufficiency.
16 January 2026 in The Journal of Clinical Endocrinology & Metabolism
Context: Adrenocorticotropic hormone (ACTH)–dependent Cushing syndrome (CS) is associated with a markedly increased risk of venous thromboembolism (VTE), yet thromboprophylaxis strategies remain inconsistent across clinical practice. In 2019, our center introduced routine oral rivaroxaban prophylaxis (10 mg once daily) for all patients with ACTH-dependent CS. Objective: To evaluate the safety and effectiveness of routine rivaroxaban prophylaxis in ACTH-dependent CS. Methods: We retrospectively reviewed 70 adults with ACTH-dependent CS managed between 2012 and 2025 (29 pre-2019 and 41 post-2019) to compare VTE incidence before and after the introduction of rivaroxaban. Results: There were no differences in baseline characteristics between the 2 groups. Cushing disease (ie, secondary to a pituitary corticotroph adenoma) was the most common subtype (26/29 pre-2019 and 34/41 post-2019). Among patients without routine prophylaxis (pre-2019), 4 patients (13.8%) developed 6 VTE events, occurring both pre- and postoperatively. In the post-2019 cohort, 5 patients experienced 7 VTE events before endocrine assessment and before rivaroxaban could be initiated. Two had recurrent VTE and were already receiving long-term treatment-dose anticoagulation; therefore, 39 of the 41 proceeded with rivaroxaban prophylaxis. No major or minor bleeding complications were observed. Hematological parameters remained stable, and all patients completed the prescribed prophylaxis course (median duration: 7.9 months). Conclusion: In our cohort, VTE incidence was 13.8% without prophylaxis and did not occur after the introduction of routine rivaroxaban. Prophylactic oral rivaroxaban in ACTH-dependent CS was safe and effective in preventing new, recurrent, perioperative, and postoperative VTE events, supporting its early initiation at diagnosis and continuation through the peri- and postoperative period.
2 April 2024 in Annals of Internal Medicine